← Leaderboards
Ali Khoshnan
University Of Southern California
$2,051,676
Attributed
$3,748,189
Total exposure
3
Grants
3
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $874.5K · FY2014–25$1M$750K$500K$250K$0
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$3,748,189 · 3
By mechanism
R01$3,291,876 · 2
R21$456,313 · 1
Top collaborators
- Ralf Langen7 shared
Most similar at University Of Southern California
Same institution · by research overlap
- Ralf Langen$16,000,439
- Rob S McConnell$18,252,821
- Jeannie Chen$21,836,703
- Silvia Angelica Cervantes$135,552
- Ansgar B Siemer$6,212,466
Others in their field
Top investigators on “In Vivo”
- David Heimbrook · Leidos Biomedical Research, Inc.$371,850,582
- Leonard Freedman · Leidos Biomedical Research, Inc.$304,459,298
- Dennis R. Burton · Scripps Research Institute$212,708,174
- Mark S Klempner · Tufts Medical Center$128,021,180
- Florian Krammer · Icahn School Of Medicine At Mount Sinai$104,723,856
- David M. Margolis · University Of Texas Sw Med Ctr/Dallas$98,374,200
Research focus
In VivoNerve DegenerationNeuronsHuntington DiseaseNeurotoxicityMutantTherapeutic TargetExonsNeurotoxicBrainPreventBiologicalConformerDiagnosticPathogenicityPathway InteractionsEpitopesCollectionIn VitroInsightHuntington GeneAntibodiesBindingLibraries
Grant awards (8)
Characterizing the Conformations and Neurotoxic Species of Huntingtin$666,988
R01 · FY2025 · NS · contact PI
Developing novel nanobody-based biosensors and therapeutics for Huntingtonâs Disease$207,500
R21 · FY2025 · NS · contact PI
Characterizing the Conformations and Neurotoxic Species of Huntingtin$612,748
R01 · FY2024 · NS · contact PI
Developing novel nanobody-based biosensors and therapeutics for Huntingtonâs Disease$248,813
R21 · FY2024 · NS · contact PI
Characterizing the Conformations and Neurotoxic Species of Huntingtin$629,795
R01 · FY2023 · NS · contact PI
Characterizing the Conformations and Neurotoxic Species of Huntingtin$505,154
R01 · FY2022 · NS · contact PI
Characterizing the Conformations and Neurotoxic Species of Huntingtin$522,029
R01 · FY2021 · NS · contact PI
Validation of IKKbeta as a therapeutic target for HD$355,162
R01 · FY2014 · NS · contact PI